



MRes in Experimental Cancer Medicine

Post-Graduate Certificate in Experimental Cancer Medicine

This programme provides students with the opportunity to work within a world class Phase 1 cancer clinical trials unit and, through a mix of taught and experiential learning, to master the discipline of experimental cancer medicine.

Students will spend a year as a member of the Experimental Cancer Medicine Team at The Christie. During this year they will participate in structured taught modules. Alongside the taught elements, students will be allocated to one or more clinical trials which are being conducted by the Christie experimental cancer medicine team. Students will have a named trainer and be exposed to tasks required in the set up, delivery, interpretation and audit of a clinical study. Nursing and physician students enrolled will be expected to participate in patient care: with physicians and nursing staff participating in new- and follow-on patient clinics, treatment and care-giving episodes with patients. For clinical trials coordinators, no direct patient contact is envisaged and duties will involve clinical trial set up, protocol amendments, database set up, data entry, costing and billing for clinical research. All students will be expected to select two aspects from their clinical trial experience and write these up as practical research projects.




Meet the Course Director: Professor Andrew Hughes

Professor Hughes is Chair of Experimental Cancer Medicine in the University of Manchester and Strategic Director of the Experimental Cancer Medicine team at The Christie. He is a member of the research strategy group for Manchester Cancer Research Centre (MCRC) which helps shape the research agenda for cancer across the University, The Christie and CRUK Manchester Institute. He serves on the Biomarker evaluation review panel for CRUK grant applications. Prior to joining MCRC, Andrew was Global Vice-President for early clinical development at AstraZeneca with oversight of some 100 Phase 0/1/2 clinical studies and prior to that Global VP for early phase clinical Oncology having been involved in over 200 early phase clinical studies

MRes in Experimental Cancer Medicine

The Christie School of Oncology and The University of Manchester

Structure of the Course



Meet the Faculty



Dr Matthew Krebs is a Clinical Senior Lecturer in Experimental Cancer Medicine at The University of Manchester and Honorary Consultant in Medical Oncology at The Christie. He has a PhD in circulating biomarkers and post-doctoral experience in single cell and ctDNA molecular profiling. He is Principal Investigator on a portfolio of phase 1 clinical trials and has research interests in clinical development of novel drugs for lung cancer and integration of biomarkers with experimental drug development.



Dr Emma Dean is Clinical Lead for the Experimental Cancer Medicine Team at The Christie, and a Clinical Senior Lecturer at The University of Manchester. She is a Principal and Co-Investigator on a broad portfolio of commercial and investigator Phase I trials, including first-in-human, first-in-combination, clinical regulatory and Phase 0 / pharmacodynamic trials. She holds a Postgraduate Certificate in Human Pharmacology and has co-supervised a European Society of Medical Oncology Translational Research Unit Visit. She is an academic advisor at The University of Manchester School of Medicine.



Dr Natalie Cook is a Senior Clinical Lecturer in Experimental Cancer Medicine at the University of Manchester and Honorary Consultant in Medical Oncology at the Christie Hospital. She completed a PhD at the University of Cambridge investigating translational therapeutics and biomarker assay design in pancreatic cancer. Prior to her current post she completed a 2 year drug development research program, based at the University of Toronto and Princess Margaret Cancer Centre, Canada. She is principal and co-investigator on a number of early phase trials and continues to develop her research interests in novel therapeutics for gastrointestinal cancers and translational biomarker design.

Who is the course for?

Doctors, nurses and clinical trial practitioners working in clinical settings. It would also be appropriate for staffing working within the pharmaceutical industry.

Scholarships: GMC-registered physicians are eligible to apply for a CRUK funded scholarship which covers both course fees and salary for the full-time MRes one year duration. Please send a copy of your CV, together with a covering letter explaining your motivation for enrolling onto the course, to the Programme Director, Professor Andrew Hughes at Andrew.hughes@manchester.ac.uk. Closing for applications is May 31 2016 but as scholarships are limited in number – please submit your interest as soon as possible.

Entry Requirements: Course applicants will have to have both an upper second class UK BSc in the Life Sciences, Pharmaceutics, biotechnology or pharmacy from any UK university, or an overseas qualification of equivalent standard as approved by University of Manchester together with existing qualifications to conduct clinical research as a General Medical Council-registered physician, Nursing and Midwifery Council-registered nurse or clinical trial coordinator including evidence of current Good Clinical Practice training.

Career paths: The MRes in Experimental Cancer Medicine is relevant to physician, nursing and clinical research students who are considering a career in Phase 1 clinical studies. It will provide a theoretical and experiential learning experience and provide a foundation for roles within other Experimental Cancer Medicine Centres within the UK and EU.

For details on application please contact: pgt.medicine@manchester.ac.uk. Further information on the course can be obtained from: <http://www.manchester.ac.uk/study/masters/courses/list/10146/mres-experimental-cancer-medicine/>